The Ultimate Longevity Stack: Epithalon, MOTS-c, SS-31, Humanin & NAD+

Aging is a multifactorial process driven by at least twelve recognized "hallmarks" — from telomere attrition and mitochondrial dysfunction to epigenetic drift and cellular senescence. No single intervention addresses all of them. This stack combines Epithalon, MOTS-c, SS-31, Humanin, and NAD+ pathway support (5-Amino-1MQ or NAD+ precursors) to target multiple hallmarks simultaneously.

Stack Overview

Mapping Peptides to the Hallmarks of Aging

The twelve hallmarks of aging, as updated by Lopez-Otin et al. in 2023, provide a framework for understanding where each peptide intervenes:

Individual Peptide Roles

Epithalon: The Telomere Guardian

Epithalon (Epitalon, AEDG peptide) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthetic analog of epithalamin, a peptide extract from the pineal gland.

• Telomerase activation — Epithalon activates the catalytic subunit of telomerase (hTERT), the enzyme responsible for maintaining telomere length. In human fibroblast cultures, Epithalon treatment reactivated telomerase and extended the replicative lifespan of cells beyond the Hayflick limit Khavinson et al., 2003
• Melatonin regulation — Restores pineal gland function and normalizes melatonin production, which declines with age. This has downstream effects on circadian rhythm, antioxidant defense, and immune function Khavinson et al., 2002
• Lifespan extension — In rodent studies, Epithalon administration extended mean lifespan by 14-31% depending on the model and dosing protocol Anisimov et al., 2001
• Cancer reduction — Paradoxically, despite activating telomerase (a hallmark of cancer), Epithalon-treated animals showed reduced spontaneous tumor incidence, possibly through improved immune surveillance and DNA repair Anisimov et al., 2003

MOTS-c: The Metabolic Optimizer

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. It was discovered in 2015 by Changhan David Lee's laboratory at USC.

• AMPK activation — MOTS-c activates AMP-activated protein kinase, the master metabolic sensor that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis Lee et al., 2015
• Nuclear translocation — Under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus where it regulates gene expression through interaction with AMPK-responsive transcription factors Kim et al., 2018
• Exercise mimetic — Improves exercise capacity, insulin sensitivity, and reduces fat accumulation, functioning as a partial exercise mimetic Reynolds et al., 2021
• Age-related decline — Endogenous MOTS-c levels decline with age. Supplementation restores metabolic parameters in aged mice to near-youthful levels

SS-31 (Elamipretide): The Mitochondrial Protector

SS-31 is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates over 1000-fold in the inner mitochondrial membrane, where it binds cardiolipin.

• Cardiolipin stabilization — Cardiolipin is a phospholipid essential for the structural integrity of mitochondrial cristae and the organization of electron transport chain (ETC) complexes. SS-31 binds cardiolipin and prevents its peroxidation, maintaining optimal ETC efficiency Birk et al., 2013
• ROS reduction — By optimizing electron flow through the ETC, SS-31 reduces electron leak and superoxide production at complexes I and III without inhibiting normal ROS signaling Zhao et al., 2004
• ATP production — Improves mitochondrial ATP production efficiency, restoring age-related declines in cellular energy output
• Clinical development — SS-31 (as elamipretide) has been in clinical trials for Barth syndrome, primary mitochondrial myopathy, age-related macular degeneration, and heart failure Szeto, 2014

Humanin: The Cytoprotective Signal

Humanin is a 24-amino acid mitochondrial-derived peptide discovered in 2001 from a cDNA library of an Alzheimer's disease patient's brain. It was the first mitochondrial-derived peptide identified with cytoprotective properties.

• Anti-apoptotic — Humanin protects cells from a variety of apoptotic insults by interacting with Bax, IGFBP-3, and tBid, preventing mitochondrial outer membrane permeabilization Hashimoto et al., 2001
• Neuroprotection — Demonstrated neuroprotective effects against amyloid-beta toxicity, oxidative stress, and serum-deprivation-induced cell death in neuronal cultures Tajima et al., 2002
• Metabolic regulation — Humanin improves insulin sensitivity and reduces hepatic glucose output through central and peripheral mechanisms Muzumdar et al., 2009
• Age-related decline — Circulating Humanin levels decline approximately 40% between ages 20 and 75, correlating with increased susceptibility to age-related pathologies Yen et al., 2020

5-Amino-1MQ: The NAD+ Restorer

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that degrades NAD+ precursors.

• NNMT inhibition — NNMT methylates nicotinamide (NAM), diverting it away from the NAD+ salvage pathway. By inhibiting NNMT, 5-Amino-1MQ increases the pool of NAM available for conversion back to NAD+ Neelakantan et al., 2017
• NAD+ restoration — Increases intracellular NAD+ levels, supporting sirtuin activity, PARP-mediated DNA repair, and mitochondrial function
• Adipocyte metabolism — Reduces fat cell differentiation and lipogenesis in vitro, with treated adipocytes showing increased oxygen consumption and decreased lipid accumulation Neelakantan et al., 2017
• Oral bioavailability — Unlike many peptides, 5-Amino-1MQ is orally bioavailable, simplifying administration

Synergy Rationale

The longevity stack works through three interconnected tiers:

Tier 1 — Genomic Maintenance (Epithalon): Maintains telomere length to prevent replicative senescence, the "clock" that limits cellular lifespan. By reactivating telomerase, Epithalon addresses the upstream driver of cellular aging.

Tier 2 — Mitochondrial Optimization (MOTS-c + SS-31 + Humanin): Three mitochondrial-derived peptides that collectively improve energy production (SS-31), metabolic signaling (MOTS-c), and cytoprotection (Humanin). This addresses the "powerhouse" decline that drives age-related functional loss.

Tier 3 — Metabolic Support (5-Amino-1MQ + MOTS-c): Restores NAD+ availability and AMPK-mediated metabolic homeostasis, fueling the enzymatic machinery (sirtuins, PARPs) that maintains cellular health.

Research Protocol

Dosing Table

Administration Notes

• Epithalon — The Khavinson protocol uses discrete 10-day courses rather than continuous administration. This is based on the bioregulatory peptide model where short courses trigger sustained biological effects. Some protocols use quarterly 10-day courses for more aggressive telomere support
• MOTS-c — Best administered in the morning or before exercise, as it activates AMPK pathways that promote glucose uptake and are naturally elevated during physical activity
• SS-31 — Can be administered at any time of day. Subcutaneous injection provides good bioavailability. In clinical trials, IV administration was used but SC is standard for research protocols
• Humanin — No specific timing requirements. Can be combined in the same injection session as MOTS-c or SS-31 for convenience
• 5-Amino-1MQ — Take orally in the morning with or without food. As a small molecule rather than a peptide, it survives gastric digestion

Sample Weekly Schedule

Epithalon is added as a 10-day overlay twice per year (e.g., January and July): 5-10mg SC daily for 10 consecutive days.

SS-31 can be added daily or 5x/week during 8-12 week cycles as needed.

Cycling Recommendations

• Epithalon: Strictly cycled. 10-day courses, 2-4 times per year. The Khavinson protocol is based on decades of research showing that short courses produce sustained telomerase activation
• MOTS-c and Humanin: Can be run continuously, as these are endogenous mitochondrial-derived peptides being supplemented to restore age-related declines. If cycling is preferred: 3 months on / 1 month off
• SS-31: 8-12 week cycles with 4-week breaks. Clinical trials have used 4-12 week courses
• 5-Amino-1MQ: Can be run continuously at lower doses (50mg) or cycled at higher doses (100mg): 8 weeks on / 4 weeks off
• Full stack rotation: Consider rotating emphasis — focus on mitochondrial peptides (MOTS-c, SS-31, Humanin) for 3 months, then shift emphasis to genomic/metabolic (Epithalon course + 5-Amino-1MQ)

Blood Work & Monitoring

Baseline Panel

Mid-Protocol (3-6 Months)

• Repeat oxidative stress markers (8-OHdG, F2-isoprostanes)
• Repeat metabolic panel (glucose, insulin, HbA1c)
• Inflammatory markers (CRP, IL-6)
• Subjective assessment: energy levels, sleep quality, cognitive function, recovery from exercise

Annual Assessment

• Telomere length — expect stabilization or modest lengthening with Epithalon courses
• Full panel repeat
• Body composition (DEXA) to track lean mass and fat changes
• Cognitive testing (standardized battery)

Safety Considerations

• Epithalon — Generally well-tolerated in clinical studies spanning 15+ years. Theoretical concern about telomerase activation in pre-cancerous cells, though animal studies paradoxically show reduced tumor incidence. Not recommended for individuals with active malignancies Khavinson et al., 2003
• MOTS-c — As an endogenous peptide, toxicity concerns are low. Limited human safety data. May lower blood glucose; monitor in diabetic individuals or those on glucose-lowering medications
• SS-31 — Extensive clinical trial safety data. Most common adverse effects: injection site reactions, headache. Well-tolerated in heart failure and mitochondrial disease patients Szeto, 2014
• Humanin — Limited human safety data despite extensive preclinical research. As an endogenous peptide present in all tissues, theoretical toxicity risk is low
• 5-Amino-1MQ — Relatively new compound with limited long-term human data. NNMT inhibition broadly affects methylation pathways; monitor liver function. Theoretical concern about altering epigenetic methylation patterns with prolonged use
• Drug interactions — MOTS-c may potentiate glucose-lowering effects of metformin and other diabetes medications. 5-Amino-1MQ may interact with medications metabolized through methylation pathways

Important: Longevity stacks are inherently long-term interventions. The limited human clinical data for several of these peptides (MOTS-c, Humanin, 5-Amino-1MQ) means that long-term safety profiles are not fully characterized. Regular blood work monitoring is essential.

References

1. Khavinson et al., 2003 — Peptide Epitalon activates chromatin at the old age
2. Khavinson et al., 2002 — Mechanisms of geroprotective effects of peptides
3. Anisimov et al., 2001 — Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice
4. Anisimov et al., 2003 — Peptide bioregulator Epithalon inhibits spontaneous carcinogenesis
5. Lee et al., 2015 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
6. Kim et al., 2018 — Mitochondrial-derived peptides as a novel AMPK regulator
7. Reynolds et al., 2021 — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
8. Birk et al., 2013 — The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
9. Zhao et al., 2004 — Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane
10. Szeto, 2014 — First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
11. Hashimoto et al., 2001 — A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta
12. Tajima et al., 2002 — Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults
13. Muzumdar et al., 2009 — Humanin: a novel central regulator of peripheral insulin action
14. Yen et al., 2020 — The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
15. Neelakantan et al., 2017 — Structure-activity relationship for small molecule inhibitors of NNMT
16. Lopez-Otin et al., 2023 — Hallmarks of aging: an expanding universe